| evidence-cartmalignancy-1 | KF1: The review frames secondary T-cell malignancy after CAR-T therapy as a safety question requiring mechanistic investigation and continued surveillance. | Its starting point is the FDA's historical safety communication, not a new patient cohort assembled by the authors. Regulatory reports are a signal and do not supply a denominator for incidence in this article. | Historical trigger: FDA communication of 28 November 2023; Therapy classes discussed: BCMA-directed and CD19-directed autologous CAR-T therapies; Article evidence level: 2024 narrative review; no original clinical safety estimate | Narrative review and explicitly attributed external evidence; no original patient-level result. | Its starting point is the FDA's historical safety communication, not a new patient cohort assembled by the authors. Regulatory reports are a signal and do not supply a denominator for incidence in this article. | Cancer Letters 597 (2024) 217083, publisher-typeset PDF p. 1, Section 1 (Introduction), and p. 4, Section 5 (Conclusions); reference 1, FDA safety communication dated 28 November 2023. | KF1 |
|---|
| evidence-cartmalignancy-2 | KF2: Vector integration is discussed as a possible route to altered growth regulation in genetically modified T cells. | The authors connect retroviral or lentiviral insertion to host-gene regulation and depict this possibility in a schematic. They do not map new integration sites or demonstrate malignant transformation in an original experiment. | Mechanistic focus: Insertional mutagenesis and dysregulated cell-growth programs; Visual support: Figure 1A, within the article's only conceptual figure; Related but distinct topic: HHV-6 reactivation is discussed; a causal HHV-6 pathway to post-CAR-T lymphoma is not established | Narrative review and explicitly attributed external evidence; no original patient-level result. | The authors connect retroviral or lentiviral insertion to host-gene regulation and depict this possibility in a schematic. They do not map new integration sites or demonstrate malignant transformation in an original experiment. | Cancer Letters 597 (2024) 217083, PDF p. 2, Section 3.1 (Insertional mutagenesis), references 14-23; p. 3, Figure 1A (conceptual schematic, not an experiment). | KF2 |
|---|
| evidence-cartmalignancy-3 | KF3: Persistent CAR signaling and an inflammatory cytokine environment are proposed as additional contexts in which malignant clones might emerge or expand. | The discussion draws on external work on activation, exhaustion, inflammation and tumor biology. These examples do not constitute a longitudinal test of malignant evolution in CAR-T recipients. | Contexts considered: Sustained cellular activation, T-cell exhaustion and inflammatory signaling; Article location: Section 3.2 and Figure 1A; Inference limit: Candidate mechanisms; no new causal effect size, mutation rate or clinical risk estimate | Narrative review and explicitly attributed external evidence; no original patient-level result. | The discussion draws on external work on activation, exhaustion, inflammation and tumor biology. These examples do not constitute a longitudinal test of malignant evolution in CAR-T recipients. | Cancer Letters 597 (2024) 217083, PDF p. 2, Section 3.2 (Sustained T-cell activation and inflammation-related cytokine-rich environment), references 24-33; p. 3, Figure 1A. | KF3 |
|---|
| evidence-cartmalignancy-4 | KF4: The review also considers host susceptibility and preceding or accompanying treatments when interpreting a malignancy diagnosed after CAR-T infusion. | Germline susceptibility, prior chemotherapy, bridging treatment and lymphodepletion are potential alternative or interacting explanations. The competing-hypothesis layout is not evidence that CAR-T therapy has no causal role. | Conceptual structure: Two hypothesis groups, illustrated in Figure 1 panels A and B; Clinical context: Prior treatment history, susceptibility and peri-infusion therapy; Excluded inference: Figure 1B supplies no statistical test of a null association | Narrative review and explicitly attributed external evidence; no original patient-level result. | Germline susceptibility, prior chemotherapy, bridging treatment and lymphodepletion are potential alternative or interacting explanations. The competing-hypothesis layout is not evidence that CAR-T therapy has no causal role. | Cancer Letters 597 (2024) 217083, PDF pp. 2 and 4, Section 3.3 (Potential susceptibility and bridging therapy considerations), references 34-52; p. 3, Figure 1B (hypothesis, not a statistical comparison). | KF4 |
|---|
| evidence-cartmalignancy-5 | KF5: Case reports, transgene assays and product-specific observations require separate interpretation before drawing a general safety conclusion. | The review discusses both CAR-positive and CAR-negative tumors and calls for continued investigation. This evidence page retains that research question while excluding inconsistent denominators and the article's broad reassurance about risk. | Evidence distinction: Detection of a CAR transgene concerns tumor origin; it is not by itself a complete causal mechanism; Numerical audit: Reference 36 confuses patients, events and biopsies; reference 37 mixes early and later follow-up populations; Supported output: A critical review framework, not a pooled incidence or proof of universal safety | Narrative review and explicitly attributed external evidence; no original patient-level result. | The review discusses both CAR-positive and CAR-negative tumors and calls for continued investigation. This evidence page retains that research question while excluding inconsistent denominators and the article's broad reassurance about risk. | Cancer Letters 597 (2024) 217083, PDF pp. 2 and 4, Section 3.3, references 36, 37, 40 and 46; p. 4, Sections 4-5. Numerical cross-check: reference 36, DOI 10.1182/blood.2022015728, Abstract, Results and Table 4 (PMC9346960); reference 37, DOI 10.1182/blood-2023-182817, Background versus Results. | KF5 |
|---|